{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:26:20Z","timestamp":1790778380500,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40259-023-00577-7","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T14:03:40Z","timestamp":1676556220000},"page":"127-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Adam","family":"Ioannou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"577_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet"},{"key":"577_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coph.2005.10.005","volume":"6","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214\u201320.","journal-title":"Curr Opin Pharmacol"},{"key":"577_CR3","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18:s30\u20135.","journal-title":"Clin Med (Lond)"},{"key":"577_CR4","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","volume":"12","author":"M Fontana","year":"2019","unstructured":"Fontana M, \u0106orovi\u0107 A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12:2345\u201356.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR5","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2022","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res Cardiovasc Res. 2022. https:\/\/doi.org\/10.1093\/cvr\/cvac119.","journal-title":"Cardiovasc Res. "},{"key":"577_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987\u20132019. N Eng J Med. 2020;382:1567\u20138.","journal-title":"N Eng J Med"},{"key":"577_CR7","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1136\/openhrt-2021-001755","volume":"8","author":"RE Lauppe","year":"2021","unstructured":"Lauppe RE, Liseth Hansen J, Gerdesk\u00f6ld C, Rozenbaum MH, Strand AM, Vakevainen M, et al. Original research: nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8:1755.","journal-title":"Open Heart."},{"key":"577_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232\u20139.","journal-title":"Ann Med"},{"key":"577_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","volume":"23","author":"JD Sipe","year":"2016","unstructured":"Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJM, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209\u201313.","journal-title":"Amyloid"},{"key":"577_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2646","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy\u2014from diagnosis to prognosis. Eur J Heart Fail. 2022. https:\/\/doi.org\/10.1002\/ejhf.2646.","journal-title":"Eur J Heart Fail"},{"key":"577_CR11","first-page":"1","volume":"1","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel R, Gillmore JD, Fontana M. Imaging-guided treatment for cardiac amyloidosis. Curr Cardiol Rep. 2022;1:1\u201312.","journal-title":"Curr Cardiol Rep"},{"key":"577_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.07.008","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, Porcari A, Knight D, Martinez-Naharro A, et al. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. JACC Cardiovasc Imaging. 2022. https:\/\/doi.org\/10.1016\/j.jcmg.2022.07.008.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MRB, Laur\u00e0 M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87:620\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"577_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/modpathol.2014.102","volume":"28","author":"A Yanagisawa","year":"2015","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28:201\u20137.","journal-title":"Mod Pathol"},{"key":"577_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA. 2017;318:962\u20133.","journal-title":"JAMA"},{"key":"577_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63\u201376.","journal-title":"Curr Med Res Opin"},{"key":"577_CR17","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35:E2403\u201312.","journal-title":"Hum Mutat"},{"key":"577_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","volume":"10","author":"M Waddington-Cruz","year":"2021","unstructured":"Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y, et al. Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther. 2021;10:753\u201366.","journal-title":"Neurol Ther."},{"key":"577_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","volume":"22","author":"DR Jacobson","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22:171\u20134.","journal-title":"Amyloid"},{"key":"577_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/13506129.2013.845745","volume":"20","author":"AM Arruda-Olson","year":"2013","unstructured":"Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, Gertz MA, Miller FA, Bielinski SJ, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013;20:263\u20138.","journal-title":"Amyloid"},{"key":"577_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med"},{"key":"577_CR22","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658\u201367.","journal-title":"JAMA"},{"key":"577_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Eng J Med. 2018;379:11\u201321.","journal-title":"N Eng J Med"},{"key":"577_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"577_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493\u2013502.","journal-title":"N Engl J Med"},{"key":"577_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.","journal-title":"Signal Transduct Target Ther"},{"key":"577_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1196\/annals.1281.007","volume":"1002","author":"NJ Caplen","year":"2003","unstructured":"Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci. 2003;1002:56\u201362.","journal-title":"Ann N Y Acad Sci"},{"key":"577_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrus. 2022;36:549\u201371.","journal-title":"BioDrus."},{"key":"577_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301\u201315.","journal-title":"Neurol Ther."},{"key":"577_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"577_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819\u201329.","journal-title":"N Engl J Med"},{"key":"577_CR32","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"HH Schmidt","year":"2022","unstructured":"Schmidt HH, Wixner J, Plant\u00e9-Bordeneuve V, Mu\u00f1oz-Beamud F, Llad\u00f3 L, Gillmore JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22:1646\u201357.","journal-title":"Am J Transplant"},{"key":"577_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","volume":"267","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020;267:703\u201312.","journal-title":"J Neurol"},{"key":"577_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431\u201343.","journal-title":"Circulation"},{"key":"577_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14:189\u201399.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR36","unstructured":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy). ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03997383. Accessed 11 Sep 2022."},{"key":"577_CR37","unstructured":"Topline Results from APOLLO-B Phase 3 Study of Patisiran. alnylampharmaceuticalsinc.gcs-web.com. https:\/\/alnylampharmaceuticalsinc.gcs-web.com\/static-files\/dc61b882-9346-4394-9f5c-dd322727742b. Accessed 11 Sep 2022."},{"key":"577_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","volume":"25","author":"TS Zimmermann","year":"2017","unstructured":"Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017;25:71\u20138.","journal-title":"Mol Ther"},{"key":"577_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","volume":"34","author":"DP Judge","year":"2022","unstructured":"Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2022;34:357\u201370.","journal-title":"Cardiovasc Drugs Ther"},{"key":"577_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine\u2013small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109:372\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"577_CR41","first-page":"1","volume":"23","author":"D Adams","year":"2022","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022;23:1\u20139.","journal-title":"Amyloid"},{"key":"577_CR42","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Vutrisiran: first approval. Drugs. 2022;82:1419\u201325.","journal-title":"Drugs"},{"key":"577_CR43","unstructured":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy-Full Text View-ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04153149. Accessed 11 Sep 2022."},{"key":"577_CR44","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1248\/bpb.b18-00625","volume":"41","author":"Y Hayashi","year":"2018","unstructured":"Hayashi Y, Jono H. Recent advances in oligonucleotide-based therapy for transthyretin amyloidosis: clinical impact and future prospects. Biol Pharm Bull. 2018;41:1737\u201344.","journal-title":"Biol Pharm Bull"},{"issue":"279","key":"577_CR45","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1074\/jbc.M311683200","volume":"2004","author":"H Wu","year":"2004","unstructured":"Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;2004(279):17181\u20139.","journal-title":"J Biol Chem"},{"key":"577_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"577_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0450-0","volume":"9","author":"JC Kaczmarek","year":"2017","unstructured":"Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9:1\u201316.","journal-title":"Genome Med."},{"key":"577_CR48","unstructured":"Tegsedi | Highlights of prescribing information. Dailymed.nlm.nih.gov. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8513207e-b55f-417b-9473-af785146a543. Accessed 12 Sep 2022."},{"key":"577_CR49","unstructured":"Tegsedi | European Medicines Agency. Ema.europa.eu\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tegsedi#authorisation-details-section. Accessed 11 Sep 2022."},{"key":"577_CR50","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ. Inotersen: First Global Approval. Drugs. 2018;78:1371\u20136.","journal-title":"Drugs"},{"key":"577_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 2016;23:148\u201357.","journal-title":"Amyloid"},{"key":"577_CR52","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","volume":"269","author":"TH Brannagan","year":"2022","unstructured":"Brannagan TH, Coelho T, Wang AK, Polydefkis MJ, Dyck PJ, Berk JL, et al. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J Neurol. 2022;269:6416\u201327.","journal-title":"J Neurol"},{"key":"577_CR53","first-page":"219","volume":"24","author":"MD Benson","year":"2017","unstructured":"Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24:219\u201325.","journal-title":"Amyloid"},{"key":"577_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27:52\u20138.","journal-title":"Amyloid"},{"key":"577_CR55","unstructured":"24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03702829. Accessed 12 Sep 2022."},{"key":"577_CR56","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796\u2013807.","journal-title":"Nucleic Acids Res"},{"key":"577_CR57","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1093\/nar\/gkx960","volume":"45","author":"M Tanowitz","year":"2017","unstructured":"Tanowitz M, Hettrick L, Revenko A, Kinberger GA, Prakash TP, Seth PP. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res. 2017;45:12388\u2013400.","journal-title":"Nucleic Acids Res"},{"key":"577_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.31","volume":"5","author":"CS Shemesh","year":"2016","unstructured":"Shemesh CS, Yu RZ, Gaus HJ, Greenlee S, Post N, Schmidt K, et al. Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys. Mol Ther Nucleic Acids. 2016;5: e319.","journal-title":"Mol Ther Nucleic Acids."},{"key":"577_CR59","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021;8:652\u201361.","journal-title":"ESC Heart Fail."},{"key":"577_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","volume":"10","author":"T Coelho","year":"2021","unstructured":"Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, et al. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther. 2021;10:375\u201389.","journal-title":"Neurol Ther."},{"key":"577_CR61","unstructured":"NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04136184. Accessed 11 Sep 2022."},{"key":"577_CR62","unstructured":"Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis | Ionis Pharmaceuticals, Inc. https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-presents-positive-results-phase-3-neuro-ttransform-study. Accessed 22 Dec 2022."},{"key":"577_CR63","unstructured":"CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). ClinicalTrials.gov. [cited 2022 Sep 14]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04136171. Accessed 11 Sep 2022."},{"key":"577_CR64","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816\u201321.","journal-title":"Science"},{"key":"577_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nature10886","volume":"482","author":"B Wiedenheft","year":"2012","unstructured":"Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482:331\u20138.","journal-title":"Nature"},{"key":"577_CR66","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A Single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22:2227\u201335.","journal-title":"Cell Rep"},{"key":"577_CR67","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMe2110557","volume":"385","author":"MS Maurer","year":"2021","unstructured":"Maurer MS. Gene editing\u2014a cure for transthyretin amyloidosis? N Eng J Med. 2021;385:558\u20139.","journal-title":"N Eng J Med"},{"key":"577_CR68","unstructured":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM). ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04601051. Accessed 19 Sep 2022."},{"key":"577_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nlm.2007.07.006","volume":"88","author":"JC Sousa","year":"2007","unstructured":"Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA. Transthyretin influences spatial reference memory. Neurobiol Learn Mem. 2007;88:381\u20135.","journal-title":"Neurobiol Learn Mem"},{"key":"577_CR70","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.neurobiolaging.2007.04.007","volume":"29","author":"J Brouillette","year":"2008","unstructured":"Brouillette J, Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging. 2008;29:1721\u201332.","journal-title":"Neurobiol Aging"},{"key":"577_CR71","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1073\/pnas.91.18.8368","volume":"91","author":"AL Schwarzman","year":"1994","unstructured":"Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"577_CR72","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1523\/JNEUROSCI.22-17-07380.2002","volume":"22","author":"TD Stein","year":"2002","unstructured":"Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380\u20138.","journal-title":"J Neurosci"},{"key":"577_CR73","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1523\/JNEUROSCI.2211-04.2004","volume":"24","author":"TD Stein","year":"2004","unstructured":"Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci. 2004;24:7707\u201317.","journal-title":"J Neurosci"},{"key":"577_CR74","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/j.1471-4159.2010.07047.x","volume":"115","author":"SD Santos","year":"2010","unstructured":"Santos SD, Lambertsen KL, Clausen BH, Akinc A, Alvarez R, Finsen B, et al. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem. 2010;115:1434\u201344.","journal-title":"J Neurochem"},{"key":"577_CR75","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/cdd.2016.64","volume":"23","author":"JR Gomes","year":"2016","unstructured":"Gomes JR, Nogueira RS, Vieira M, Santos SD, Ferraz-Nogueira JP, Relvas JB, et al. Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ. 2016;23:1749\u201364.","journal-title":"Cell Death Differ"},{"key":"577_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10238-010-0103-8","volume":"11","author":"C Gao","year":"2011","unstructured":"Gao C, Zhang B, Zhang W, Pu S, Yin J, Gao Q. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clin Exp Med. 2011;11:49\u201354.","journal-title":"Clin Exp Med"},{"key":"577_CR77","doi-asserted-by":"publisher","first-page":"24238","DOI":"10.1038\/srep24238","volume":"6","author":"F Zheng","year":"2016","unstructured":"Zheng F, Kim YJ, Moran TH, Li H, Bi S. Central transthyretin acts to decrease food intake and body weight. Sci Rep. 2016;6:24238.","journal-title":"Sci Rep"},{"key":"577_CR78","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1530\/EJE-11-0431","volume":"165","author":"P Kotnik","year":"2011","unstructured":"Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol. 2011;165:703\u201311.","journal-title":"Eur J Endocrinol"},{"key":"577_CR79","doi-asserted-by":"publisher","first-page":"E785","DOI":"10.1152\/ajpendo.00521.2007","volume":"294","author":"N Mody","year":"2008","unstructured":"Mody N, Graham TE, Tsuji Y, Yang Q, Kahn BB. Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob\/ob mice. Am J Physiol Endocrinol Metab. 2008;294:E785\u201393.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"577_CR80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cmet.2007.06.002","volume":"6","author":"N Kl\u00f6ting","year":"2007","unstructured":"Kl\u00f6ting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6:79\u201387.","journal-title":"Cell Metab"},{"key":"577_CR81","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2337\/db14-0970","volume":"64","author":"L Zemany","year":"2015","unstructured":"Zemany L, Bhanot S, Peroni OD, Murray SF, Moraes-Vieira PM, Castoldi A, et al. Transthyretin antisense oligonucleotides lower circulating RBP4 levels and improve insulin sensitivity in obese mice. Diabetes. 2015;64:1603\u201314.","journal-title":"Diabetes"},{"key":"577_CR82","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927\u201330.","journal-title":"Nat Med"},{"key":"577_CR83","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","volume":"52","author":"OM Enache","year":"2020","unstructured":"Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52:662\u20138.","journal-title":"Nat Genet"},{"key":"577_CR84","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","volume":"30","author":"G Merlini","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30:1979\u201386.","journal-title":"Leukemia"},{"key":"577_CR85","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1515\/CCLM.2004.108","volume":"42","author":"M Emdin","year":"2004","unstructured":"Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627\u201336.","journal-title":"Clin Chem Lab Med"},{"key":"577_CR86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","volume":"6","author":"SM Banypersad","year":"2013","unstructured":"Banypersad SM, Sado DM, Flett AS, Gibbs SDJ, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34\u20139.","journal-title":"Circ Cardiovasc Imaging"},{"key":"577_CR87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2217\/bmm-2019-0039","volume":"13","author":"C Passino","year":"2019","unstructured":"Passino C, Aimo A, Masotti S, Musetti V, Prontera C, Emdin M, et al. Cardiac troponins as biomarkers for cardiac disease. Biomark Med. 2019;13:325\u201330.","journal-title":"Biomark Med"},{"key":"577_CR88","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","volume":"100","author":"A Dispenzieri","year":"2014","unstructured":"Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014;100:383\u20138.","journal-title":"Heart"},{"key":"577_CR89","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jcmg.2020.12.009","volume":"14","author":"D Kim","year":"2021","unstructured":"Kim D, Choi JO, Kim K, Kim SJ, Kim JS, Jeon ES. Association of left ventricular global longitudinal strain with cardiac amyloid load in light chain amyloidosis. JACC Cardiovasc Imaging. 2021;14:1283\u20135.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR90","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","volume":"43","author":"OC Cohen","year":"2022","unstructured":"Cohen OC, Ismael A, Pawarova B, Manwani R, Ravichandran S, Law S, et al. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. Eur Heart J. 2022;43:333\u201341.","journal-title":"Eur Heart J"},{"key":"577_CR91","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26:753\u20139.","journal-title":"J Card Fail"},{"key":"577_CR92","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","volume":"24","author":"L Chacko","year":"2022","unstructured":"Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24:1700\u201312.","journal-title":"Eur J Heart Fail"},{"key":"577_CR93","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jacc.2018.12.054","volume":"73","author":"D Dey","year":"2019","unstructured":"Dey D, Slomka PJ, Leeson P, Comaniciu D, Shrestha S, Sengupta PP, et al. Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:1317\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"577_CR94","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2589-7500(21)00235-1","volume":"4","author":"J Tromp","year":"2022","unstructured":"Tromp J, Seekings PJ, Hung CL, Iversen MB, Frost MJ, Ouwerkerk W, et al. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Lancet Digit Health. 2022;4:e46-54.","journal-title":"Lancet Digit Health."},{"key":"577_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/heartjnl-2020-318686","volume":"108","author":"JP Howard","year":"2022","unstructured":"Howard JP, Francis DP. Machine learning with convolutional neural networks for clinical cardiologists. Heart. 2022;108:73\u201381.","journal-title":"Heart"},{"key":"577_CR96","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570\u20139.","journal-title":"Circulation"},{"key":"577_CR97","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157\u201365.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR98","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","volume":"6","author":"TD Karamitsos","year":"2013","unstructured":"Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6:488\u201397.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR99","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","volume":"36","author":"SM Banypersad","year":"2015","unstructured":"Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. Editor\u2019s choice: T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36:244\u201351.","journal-title":"Eur Heart J"},{"key":"577_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac363","author":"A Martinez-Naharro","year":"2022","unstructured":"Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022. https:\/\/doi.org\/10.1093\/eurheartj\/ehac363.","journal-title":"Eur Heart J"},{"key":"577_CR101","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"577_CR102","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18 F-flutemetamol positron emission tomography. Ann Nucl Med. 2019;33:624\u20138.","journal-title":"Ann Nucl Med"},{"key":"577_CR103","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsj\u00f6 L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213\u201320.","journal-title":"J Nucl Med"},{"key":"577_CR104","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, Vergaro G, Giorgetti A, Marzullo P, Scipioni M, Santarelli MF, et al. [18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging. 2021;14:246\u201355.","journal-title":"JACC Cardiovasc Imaging"},{"key":"577_CR105","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kort\u00fcm KM, et al. Detection of cardiac amyloidosis with 18 F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46:1407\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"577_CR106","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"SP Lee","year":"2020","unstructured":"Lee SP, Suh HY, Park S, Oh S, Kwak SG, Kim HM, et al. Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol. 2020;75:380\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"577_CR107","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Ha S, Kim YL. Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol. 2020;27:123\u201332.","journal-title":"J Nucl Cardiol"},{"key":"577_CR108","unstructured":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03860935. Accessed 20 Nov 2021."},{"key":"577_CR109","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146:1657\u201370.","journal-title":"Circulation"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00577-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T10:04:27Z","timestamp":1678183467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00577-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00577-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"10 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Adam Ioannou, Marianna Fontana and Julian Gillmore were all involved in writing and editing the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Adam Ioannou does not have any conflicts of interest. Marianna Fontana is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS\/18\/21\/33447) and has consulting income from Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Alnylam, Alexion, Janssen and Ionis. Julian Gillmore has consulting income from Ionis, Alexion, Eidos, Intellia, Alnylam and Pfizer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This work did not receive any specific funding.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}